{"Clinical Trial ID": "NCT00300781", "Intervention": ["INTERVENTION 1:", "Neratinib 240, Trastuzumab anterior", "Neratinib: 80 mg of capsules and 40 mg of coated tablets taken orally at the prescribed dose of 240 mg daily, as long as the disease is tolerated and the disease does not worsen in participants who received treatment prior to trastuzumab.", "INTERVENTION 2:", "Neratinib 240, No anterior trastuzumab", "Neratinib: 80 mg of capsules and 40 mg of coated tablets taken orally at the prescribed dose of 240 mg daily, as long as the disease is tolerated and the disease does not worsen in participants who have not already received trastuzumab treatment."], "Eligibility": ["Incorporation criteria:", "\u2022 Pathological diagnosis of breast cancer and current stage IIIB, IIIC or IV", "\u2022 Progression after at least 6 weeks of standard doses of Herceptin (Arm A only)", "Overexpression of HER2", "The available and adequate tumour tissues for screening testing", "At least one measurable injury", "- Exclusion criteria:", "Previous treatment with Herceptin (Arm B only)", "More than 4 previous cytotoxic chemotherapys", "Subjects presenting a bone or skin as the only measurable disease site", "Insufficiency of cardiac function", "\u2022 Major surgery, chemotherapy, radiotherapy, research agents or other cancer treatment within one week of treatment day 1", "Metastasis of the active central nervous system", "Pregnant or lactating women", "Could not swallow HKI-272 capsules"], "Results": ["Performance measures:", "\u2022 Survival without 16 weeks of progression", "In women with positive breast cancer of the human epidermal growth factor (HER2), 16-week Neratinib progression-free survival rate (PFS) in either pre-trastuzumab treatment or no pre-trastuzumab treatment, evaluated by independent evaluation of tumour analyses collected at baseline and every 8 weeks thereafter.", "Duration: from first dose to 16 weeks", "Results 1:", "Title of the arm/group: Neratinib 240, Prior Trastuzumab", "Description of the arm/group: Neratinib: 80 mg hard capsules and 40 mg coated tablets taken orally at the prescribed dose of 240 mg daily, as long as tolerated and the disease does not worsen in participants who received treatment prior to trastuzumab.", "Total number of participants analysed: 66", "Type of measurement: Number", "Unit of measure: percentage of participants 58.2 (45.3 to 71.2)", "Results 2:", "Title of arm/group: Neratinib 240, No anterior trastuzumab", "Description of the arm/group: Neratinib: 80mg capsules and 40mg coated tablets taken orally at the prescribed dose of 240mg daily, as long as tolerated and disease does not worsen in participants without prior treatment with trastuzumab.", "Total number of participants analysed: 70", "Type of measurement: Number", "Unit of measure: percentage of participants 77.8 (67.6 to 88.1)"], "Adverse Events": ["Undesirable Events 1:", "Total: 19/66 (28.79%)", "Anemia 0/66 (0.00 %)", "Atrioventricular block 0/66 (0.00 %)", "Bradycardia 0/66 (0.00 %)", "Diarrhoea 4/66 (6.06%)", "Nausea 2/66 (3.03%)", "Vomiting 3/66 (4.55%)", "Asthenia 0/66 (0.00 %)", "Fatigue 1/66 (1.52%)", "- Malays 0/66 (0.00 %)", "Pyrexia 0/66 (0.00 %)", "Disseminated tuberculosis 0/66 (0.00 %)", "Folliculitis 0/66 (0.00 %)", "Hepatitis E 0/66 (0.00 per cent)", "Adverse Events 2:", "Total: 17/70 (24.29%)", "Anemia 1/70 (1.43%)", "Auriventricular block 1/70 (1.43%)", "Bradycardia 1/70 (1.43%)", "Diarrhoea 4/70 (5.71%)", "- Nausea 0/70 (0.00 %)", "Vomiting 6/70 (8.57 per cent)", "Asthenia 1/70 (1.43%)", "- Fatigue 0/70 (0.00 %)", "- Malaise 1/70 (1.43%)", "Pyrexia 1/70 (1.43%)", "Disseminated tuberculosis 1/70 (1.43%)", "Folliculitis 1/70 (1.43%)", "Hepatitis E 1/70 (1.43%)"]}